Affectis Pharmaceuticals AG Announces Target Validation Collaboration with Mitsubishi Pharma
Affectis Pharmaceuticals AG announced that it has signed a collaboration agreement with Mitsubishi Pharma Corporation for the development of novel therapeutics for the treatment of affective disorders. Under the terms of the agreement, Affectis will apply its pioneering target validation technology and its exclusive animal models for the validation of Mitsubishi Pharma's gene targets involved in depression and anxiety.
Today, one of the major challenges in developing optimised drugs against affective disorders is the limited availability of suitable animal models and sufficient expertise in selecting promising targets and leads as well as their preclinical development. Affectis´ team has experience in developing, performing and interpreting behavioural assays and animal models of diseases such as depression and anxiety.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.